SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

UBI Universal Biosensors Inc

Healthcare · Medical Devices · website · 76 employees
$0.01
52wk 0.01 – 0.01
Overall
48.9
Value
100.0
Growth
22.4
Health
53.4
Quality
0.0
Momentum
59.3
Dividend
—
Price
About Universal Biosensors Inc

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.

Price analytics

Returns

1 day 0.0%
1 week 0.0%
1 month 0.0%
3 months 0.0%
6 months 0.0%
1 year 0.0%
3 years -93.9%

Risk

Volatility (1y ann.) 0.0%
Beta vs ASX 200 0.00
Sharpe (1y) —
VaR 95% (1-day) 0.0%
Max drawdown (1y) 0.0%
Off 1-year high 0.0%

Technicals

RSI(14) 100 OB
vs 50DMA 0.0%
vs 200DMA 0.0%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 100.0
Trailing P/E
—
Forward P/E
100
PEG ratio
100
EV / EBITDA
100
Price / Book
100
Price / Sales
100
Growth 22.4
Revenue growth (1y)
14
Revenue CAGR (3y)
31
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 53.4
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
65
Debt / Equity
87
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 59.3
6-month return vs ASX 200
46
Price vs 200-day average
50
Price vs 50-day average
50
Position in 52-week range
100

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$4.17M
P/E (trailing)
—
P/E (forward)
-0.35
EPS (trailing)
-0.06
Dividend yield
—
Payout ratio
0.0%
Beta
0.21
EV / EBITDA
-0.26
Price / Book
0.58
ROE
-111.0%
Operating margin
-554.7%
Net margin
-293.3%
Total cash
$2.20M
Total debt
$3.05M
Current ratio
1.90
Debt / Equity
0.43
Free cash flow
$-9.10M
Avg volume
—
Latest annual results (FY ending 31 Dec 2024)
  • Revenue$6.28M
  • Gross profit$4.00M
  • Operating income-$14.76M
  • Net income-$14.24M
  • Diluted EPS-0.05
  • Free cash flow-$12.71M
  • Net debt-$4.53M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4